MedTrace Logo

Prostate Cancer Genetic Risk Evaluation and Screening Study

NCT05129605 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-10-09

No results posted yet for this study

Summary

This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.

Conditions

  • Prostatic Neoplasm
  • Prostate Cancer
  • BRCA2 Mutation
  • BRCA1 Mutation
  • ATM Gene Mutation
  • MMR Mutation
  • Lynch Syndrome
  • Genetic Predisposition to Disease

Interventions

DIAGNOSTIC_TEST

Prostate cancer screening

Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Keyan Salari, MD, PhD · Massachusetts General Hospital

Eligibility

Min Age
35 Years
Max Age
74 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-12
Primary Completion
2030-12-31
Completion
2040-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05129605 on ClinicalTrials.gov